Drug Discovery market research reports by DelveInsight

• Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024 DelveInsight’s, “Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Primary Progressive Multiple Sclerosis pipeline landscape. It covers t ... Read More

• 5-Alpha Reductase Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  5-Alpha Reductase Inhibitor - Pipeline Insight, 2024 “5-Alpha Reductase Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-Alpha Reductase Inhibitor development. The report p ... Read More

• Transverse Myelitis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Transverse Myelitis - Pipeline Insight, 2024 Transverse Myelitis Overview ""Transverse Myelitis Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Transverse Myelitis market. A detailed picture of th ... Read More

• 5-HT2B Antagonist - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  5-HT2B Antagonist - Pipeline Insight, 2024 “5-HT2B Antagonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT2B Antagonist development. The report provides detailed coverage of t ... Read More

• 20s Proteasome Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  20s Proteasome Inhibitor - Pipeline Insight, 2024 “20s Proteasome Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 20s Proteasome Inhibitor development. The report provides d ... Read More

• 5-HT6 Antagonist - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  5-HT6 Antagonist - Pipeline Insight, 2024 “5-HT6 Antagonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT6 Antagonist development. The report provides detailed coverage of the ... Read More

• Urinary Incontinence Including Neurogenic Bladder - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Urinary Incontinence Including Neurogenic Bladder - Pipeline Insight, 2024 Urinary Incontinence Including Neurogenic Bladder Overview ""Urinary Incontinence Including Neurogenic Bladder Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development sce ... Read More

• Uveal Neoplasms - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Uveal Neoplasms - Pipeline Insight, 2024 Uveal Neoplasms Overview ""Uveal Neoplasms Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Uveal Neoplasms market. A detailed picture of the Uveal Neoplasm ... Read More

• 5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2024 “5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and gro ... Read More

• 5-HT4 Antagonist - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  5-HT4 Antagonist - Pipeline Insight, 2024 “5-HT4 Antagonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Antagonist development. The report provides detailed coverage of the ... Read More

• Urolithiasis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Urolithiasis - Pipeline Insight, 2024 Urolithiasis Overview ""Urolithiasis Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Urolithiasis market. A detailed picture of the Urolithiasis pipeline land ... Read More

• Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2024 DelveInsight’s, “Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers ... Read More

• Selectin Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Selectin Inhibitor - Pipeline Insight, 2024 “Selectin Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Selectin Inhibitor development. The report provides detailed coverage o ... Read More

• Serotonin Transporter Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Serotonin Transporter Inhibitor - Pipeline Insight, 2024 “Serotonin Transporter Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Serotonin Transporter Inhibitor development. ... Read More

• Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2024 “Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Serotonin Reuptake Inhibitor (SRI) deve ... Read More

• Severe Hypoglycemia - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Severe Hypoglycemia - Pipeline Insight, 2024 Severe Hypoglycemia Overview ""Severe Hypoglycemia Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Severe Hypoglycemia market. A detailed picture of th ... Read More

• Retinitis Pigmentosa- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Retinitis Pigmentosa- Pipeline Insight, 2024 DelveInsight’s, “Retinitis Pigmentosa- Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and noncl ... Read More

• Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2034

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 3,950

  Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2034 Key Highlights DelveInsight’s analyst projects that among the total diagnosed prevalent cases of FSGS in 7MM approximately 202 thousand with 36% of cases were from the US. According to the analysis conducted by DelveInsight’s, ... Read More

• Staphylococcus Aureus Infection - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Staphylococcus Aureus Infection - Pipeline Insight, 2024 Staphylococcus Aureus Infection Overview ""Staphylococcus Aureus Infection Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Staphylococcus A ... Read More

• Anorexia Nervosa - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anorexia Nervosa - Pipeline Insight, 2024 DelveInsight’s, “Anorexia Nervosa - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anorexia Nervosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stag ... Read More

• Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024 DelveInsight’s, “Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Interleukin-18 (IL-18) Inhibitor pipeline landscape. It covers the pipeline drug p ... Read More

• Advanced Renal Cell Carcinoma- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,500

  Advanced Renal Cell Carcinoma- Pipeline Insight, 2024 DelveInsight’s, “Advanced Renal Cell Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, i ... Read More

• H3N2 infection - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  H3N2 infection - Pipeline Insight, 2024 DelveInsight’s, “H3N2 infection- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage prod ... Read More

• Rett Syndrome - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Rett Syndrome - Pipeline Insight, 2024 DelveInsight’s, “Rett Syndrome - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Rett Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage produ ... Read More

• Celiac Disease- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Celiac Disease- Pipeline Insight, 2024 DelveInsight’s, “Celiac Disease- Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Celiac Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage prod ... Read More

< prev 37 38 39 40 41 42 43 44 45 46 next >